financetom
Business
financetom
/
Business
/
After tariffs, French business lobby says it got it wrong on Trump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
After tariffs, French business lobby says it got it wrong on Trump
Apr 9, 2025 1:54 AM

PARIS, April 9 (Reuters) - The leader of the main French

business federation, Patrick Martin, said on Wednesday he had

got it wrong on U.S. President Donald Trump, saying French firms

who applauded pro-business policies in January did not imagine

he would go ahead with tariffs.

Trump stunned business leaders on both sides of the Atlantic

when he unveiled a range of sweeping new tariffs on dozens of

U.S. trading partners on what he called "Liberation Day",

causing a stock market meltdown across the globe.

Many French business leaders had initially feted Trump's

return to power, with LVMH CEO Bernard Arnault, who attended his

inauguration, talking about a "wind of optimism" in the U.S. and

shipping giant CMA CGM announcing a massive investment there.

Asked on RTL radio if business leaders regretted their

fascination or enthusiasm for Trump, Martin, the head of Medef,

which represents corporate giants such as Totalenergies

, LVMH and L'Oreal, said he did.

"I wouldn't say there was fascination or enthusiasm for

Trump, but yes, in a way, I take back what I said," Martin said.

"At the time, we acknowledged how well the U.S. economy was

doing and Trump's pro-business policies. We didn't imagine he

would implement what he had promised during his campaign --

tariffs that many think will be fatal for the U.S. market."

Trump's "reciprocal" tariffs on dozens of countries took

effect on Wednesday, including massive 104% duties on Chinese

goods, deepening his global trade war even as he prepared for

negotiations with some nations.

French President Emmanuel Macron told business leaders last

week that European companies should suspend planned investment

in the United States for now, to avoid undermining European

efforts to negotiate with the Trump administration.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved